AgomAb Therapeutics NV, a clinical-stage biopharmaceutical company, develops novel disease-modifying therapies for immunology and inflammatory diseases with a focus on chronic fibrotic indications with unmet medical needs. The company's product pipeline includes Ontunisertib (AGMB-129), an oral gastrointestinal-restricted small molecule inhibitor of ALK5 or TGFßR1 for the treatment of Fibrostenosing Crohn's disease, which is in Phase 2a clinical trials; and AGMB-447, an inhaled small molecule in...
Mar 26, 2026, 7:00 AM EDT - 10 days ago
Feb 9, 2026, 4:05 PM EST - 7 weeks ago
Feb 6, 2026, 12:48 PM EST - 2 months ago
Feb 5, 2026, 7:24 PM EST - 2 months ago
Jan 16, 2026, 4:43 PM EST - 2 months ago
Jan 16, 2026, 4:19 PM EST - 2 months ago